| LEADER |
Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results |
NCT01179048 |
| SUSTAIN-6 |
Cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes |
NCT01720446 |
| HARMONY |
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease |
NCT02465515 |
| FIGHT14 |
Functional impact of GLP-1 for heart failure treatment |
NCT01800968 |
| LIRA-RENAL12 |
Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment |
NCT01620489 |
| SAVOR-TIMI 53 |
The saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus [SAVOR]–thrombolysis in myocardial infarction [TIMI] 53 |
NCT01107886 |
| TECOS |
Trial evaluating cardiovascular outcomes with sitagliptin |
NCT00790205 |
| VERIFY |
Vildagliptin efficacy in combination with metformIn for early treatment of type 2 diabetes |
NCT01528254 |
| EXAMINE |
Examination of cardiovascular outcomes with alogliptin versus standard of care |
NCT00968708 |
| CANVAS |
Canagliflozin cardiovascular assessment study |
NCT01032629 |
| EMPA-REG OUTCOME |
Empagliflozin cardiovascular outcome event trial |
NCT01131676 |
| DECLARE-TIMI 58 |
Dapagliflozin effect on cardiovascular events–thrombolysis in myocardial infarction 58 |
NCT01730534 |
| SCORED |
Sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes and moderate renal impairment who are at cardiovascular risk |
NCT03315143 |
| SOLOIST-WHF |
Sotagliflozin on cardiovascular events in patients with type 2 diabetes post worsening heart failure |
NCT03521934 |
| VERTIS |
Evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial |
NCT01986881 |
| UKPDS |
The UK prospective diabetes study |
ISRCTN75451837 |
| ADVANCE |
Blood pressure and glucose lowering for the prevention of vascular disease in high risk patients with type 2 diabetes |
NCT00145925 |
| ACCORD |
Action to control cardiovascular risk in diabetes |
NCT00000620 |
| VADT |
Veterans Affairs diabetes trial |
NCT00032487 |
| ELIXA |
Evaluation of lixisenatide in acute coronary syndrome |
NCT01147250 |
| EXSCEL |
Exenatide study of cardiovascular event lowering |
NCT01144338 |
| PIONEER 6 |
Peptide innovation for early diabetes treatment |
NCT02692716 |
| REWIND |
Researching cardiovascular events with a weekly incretin in diabetes |
NCT01394952 |
| CARMELINA |
Cardiovascular and renal microvascular outcome study with linagliptin |
NCT01897532 |
